Stockreport

BioMarin starts Phase 1/2 study of gene therapy for hemophilia A subgroup [Seeking Alpha]

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
PDF BioMarin starts Phase 1/2 study of gene therapy for hemophilia A subgroupDosing is underway in a Phase 1/2 clinical trial,BMN 270-203, assessing BioMarin Pharmaceutical' [Read more]